ADVFN UK Market News

Category: Market News

  • FTSE 100 today: Stocks edge higher as Middle East tensions keep investors cautious

    FTSE 100 today: Stocks edge higher as Middle East tensions keep investors cautious

    UK equities moved higher at the open on Friday following a turbulent week for global markets, with investors continuing to monitor developments related to the Middle East conflict. The situation in the region is expected to remain a key influence on sentiment, while the pound strengthened against the dollar and major European indices also traded higher.

    At 08:14 GMT, the FTSE 100 was up 0.2%. Sterling also gained ground, with GBP/USD rising 0.1% to 1.3369 against the dollar. On the continent, Germany’s DAX advanced 0.9% and France’s CAC 40 added 0.4%.

    Middle East update

    U.S. President Donald Trump said he would oppose Mojtaba Khamenei becoming Iran’s next leader, while Tehran said it has no interest in entering negotiations.

    Some reports offered a more constructive development, suggesting China is holding discussions with Iran aimed at ensuring the safe passage of vessels through the Strait of Hormuz.

    At the same time, Washington is reportedly considering a range of options to help stabilise oil prices, including the possibility of temporarily easing restrictions on Russian crude supplies.

    “Near term, we still see an upward pressure on oil prices, and we could see oil above $90. But we are not in the camp that oil could go above $100 and stay there for an elongated period of time,” according to Jefferies.

    UK round up

    IMI PLC (LSE:IMI) unveiled a £500 million share buyback after reporting its fifth straight year of mid-single digit organic revenue growth. The British fluid and motion control specialist said adjusted earnings per share increased 8% to 132.3p in 2025.

    The FTSE 100 group reported a 5% rise in organic revenue to £2.30 billion, while adjusted operating profit climbed 8% on an organic basis to £460 million. This lifted the adjusted operating margin by 30 basis points to 20.0%. Statutory operating profit increased 19% to £422 million.

    Looking ahead, IMI expects adjusted basic EPS for 2026 to range between 136p and 140p, which would mark a sixth consecutive year of mid-single digit organic revenue growth.

    Elsewhere in UK corporate news, Marwyn Acquisition Company III Ltd (LSE:MAC3) confirmed that discussions with Palmer Street Limited regarding a possible business combination have ended by mutual agreement.

    The negotiations, originally announced on 9 October 2025, were discontinued after both sides concluded that pursuing a public listing would be premature at the present time.

    In economic data, UK house prices reached a new record in February, according to figures released by Halifax. The average property price rose to £301,151.

    Prices increased 0.3% during the month, following January’s 0.8% gain. On an annual basis, growth accelerated to 1.3% from 1.1% previously, the strongest rate recorded in four months. Since the beginning of the year, average house prices have risen by roughly £3,000.

  • Valirx Launches Animal Health Subsidiary to Expand Oncology Platform

    Valirx Launches Animal Health Subsidiary to Expand Oncology Platform

    Valirx plc (LSE:VAL) has announced the creation of a wholly owned subsidiary, Valirx Animal Health Ltd, marking a strategic expansion into the rapidly growing animal health sector while maintaining its core focus on oncology drug development.

    Speaking on The Watchlist, Valirx CEO Mark Eccleston explained that the move is designed to complement the company’s existing human therapeutics pipeline while opening new commercial and research opportunities in veterinary medicine.

    A Growing Market Opportunity

    The global animal health market is experiencing steady growth and is projected to reach approximately $5 billion by 2030 in the oncology segment alone, comparable in size to the triple-negative breast cancer market, one of Valirx’s key targets in human medicine.

    Eccleston said the opportunity lays in developing treatments that can benefit both animals and humans.

    “Comparative oncology allows us to develop drugs for animals in animals, but the research also benefits the human market,” he said. “It’s essentially a parallel development stream.”

    Comparative oncology studies naturally occurring cancers in animals, particularly dogs, to generate insights that may accelerate human drug development. Because many cancers in dogs behave similarly to those in humans, the approach can provide valuable data on treatment response, safety, and disease biology.

    Complementing the Human Oncology Pipeline

    Valirx has historically focused on oncology drug development and asset partnering. According to Eccleston, the creation of the animal health subsidiary is not a shift in strategy but rather an extension of a model the company has long considered.

    He noted that ValiRx’s first spin out, Volition, has had success in veterinary diagnostics with a point of care canine cancer screening test which was ultimately sold for $28 million, before the equivalent human diagnostic was fully developed.

    “Animal health offers faster access to markets and lower regulatory barriers,” Eccleston explained. “It allows us to potentially bring clinical products to market more quickly, generating revenue while supporting our human research.”

    The biological similarities between cancers in dogs and humans mean data gathered in veterinary trials can also strengthen the human drug development pathway.

    “All the safety testing and profiling work done in the canine side complements what happens on the human side,” he added.

    Hub-and-Spoke Investment Model

    The new subsidiary also fits into Valirx’s broader corporate structure, which Eccleston described as a “hub and spoke” model.

    Under this structure, Valirx acts as the central hub while individual assets are placed into special purpose vehicles (SPVs). These SPVs can attract targeted investment while remaining linked to the parent company.

    Valirx Animal Health will operate as a dedicated veterinary SPV, with oncology assets from other divisions potentially cross-licensed into the subsidiary.

    This model provides flexibility for investors.

    “If you want to invest in the main company, you can,” Eccleston said. “But if you want to focus on a specific asset or the veterinary medicine market, this structure opens those opportunities.”

    The approach could also create additional funding pathways for the company by allowing external investors to participate directly in individual programs or sectors.

    Outlook for the Next Two Years

    Over the next 12 to 24 months, Valirx expects the animal health division to play a key role in expanding optionality across its portfolio. By combining human oncology research with veterinary applications, the company aims to accelerate development timelines, attract new investment, and unlock additional value from its intellectual property.

    While the company’s primary identity remains rooted in human oncology innovation, the launch of Valirx Animal Health signals a broader ambition: leveraging comparative oncology to advance treatments for both humans and animals.

    For more information on Valirx visit – https://valirx.com/

  • Pantheon Resources Announces Departure of Senior Non-Executive Director

    Pantheon Resources Announces Departure of Senior Non-Executive Director

    Pantheon Resources plc (LSE:PANR) has confirmed that senior non-executive director Linda Havard has stepped down from the board with effect from 5 March 2026 and will not stand for re-election at the company’s upcoming annual general meeting. During her tenure, Havard chaired the Finance, Audit and Risk Committee and played a key role in strengthening the company’s financial governance and reporting framework, contributing to board oversight as Pantheon advances its major development projects in Alaska.

    Her departure comes as the company continues to move forward with development plans for its Ahpun and Kodiak projects on Alaska’s North Slope. Both assets hold significant independently certified contingent resources and benefit from proximity to established infrastructure. Pantheon has not yet announced a replacement for the board position, and the change in governance may draw attention from investors given the scale and capital requirements of the company’s planned developments.

    The company’s outlook remains constrained by weak financial fundamentals, including recurring losses and negative free cash flow. Technical indicators also point to bearish sentiment, with the share price trading below key moving averages. Valuation metrics offer limited support, as the negative price-to-earnings ratio reflects ongoing unprofitable operations and the company does not currently pay a dividend.

    More about Pantheon Resources

    Pantheon Resources plc is an AIM-listed oil and gas company focused on developing its wholly owned Ahpun and Kodiak fields on Alaska’s North Slope. The company controls approximately 259,000 acres of state land and reports independently certified contingent recoverable resources of about 1.6 billion barrels of Alaska North Slope crude and 6.6 trillion cubic feet of associated natural gas. Its assets benefit from access to nearby roads and pipeline infrastructure.

    Pantheon’s strategy aims to unlock an estimated value of around $5 per barrel of recoverable resources by bringing the Ahpun project to final investment decision and first production through the Trans Alaska Pipeline System. Cash flow from Ahpun is expected to support the future development of Kodiak, while gas resources may be monetised through a precedent agreement with the Alaska Gasline Development Corporation tied to a proposed long-distance pipeline to Southcentral Alaska.

  • Avon Technologies Wins $12.7m CBRN Filter Order Supporting FY2026 Outlook

    Avon Technologies Wins $12.7m CBRN Filter Order Supporting FY2026 Outlook

    Avon Technologies (LSE:AVON) has secured a new order valued at approximately $12.7 million for its MILCF50 CBRN filters from an existing customer in the Middle East that already uses the company’s respirator systems. The filters are designed to protect users from chemical and biological warfare agents in various forms and feature a low-profile, conformal design, highlighting Avon’s focus on specialised protective equipment for high-risk environments.

    The company said the contract is expected to contribute to its financial performance for the 2026 fiscal year and remains consistent with the guidance issued in late 2025. The order also reflects ongoing global demand for CBRN protection systems, reinforcing Avon’s position in a highly specialised segment of the defence equipment market.

    While recent corporate developments and positive commentary from the latest earnings call point to strong revenue and profit growth, the company’s broader outlook remains mixed. Financial metrics indicate ongoing challenges related to profitability and liquidity, while technical indicators suggest bearish market momentum, tempering the otherwise positive strategic progress.

    More about Avon Technologies

    Avon Technologies is a specialist manufacturer of protective equipment used by military personnel and law enforcement agencies worldwide. Its products are used by more than 4 million service members and first responders across more than 70 markets.

    The company operates through two primary divisions: Avon Protection, which develops advanced respiratory and integrated CBRN protection systems, and Team Wendy, which produces high-performance ballistic and impact protection helmet systems. Through ongoing investment in innovation and technology, Avon aims to enhance safety and performance for personnel operating in demanding and hazardous environments.

  • Blencowe Expands Orom-Cross Graphite Resource with Maiden Iyan Deposit Estimate

    Blencowe Expands Orom-Cross Graphite Resource with Maiden Iyan Deposit Estimate

    Blencowe Resources (LSE:BRES) has reported a maiden JORC 2012 mineral resource estimate for the newly identified Iyan deposit at its Orom-Cross Graphite Project in Uganda. The initial estimate outlines 16.9 million tonnes grading 6.0% total graphitic carbon (TGC) in the Inferred category. With the inclusion of Iyan, the total JORC mineral resource at Orom-Cross increases by 66% to 43.0 million tonnes at an average grade of 5.76% TGC. The updated resource spans the Northern Syncline, Camp Lode and Iyan deposits, all reported using a 3.5% cut-off grade.

    The company noted that mineralisation at Iyan remains open both along strike and at depth, with several drill holes terminating in mineralised zones, suggesting potential for further expansion. Additional upside could also come from the nearby Beehive discovery once assay results are incorporated into a future resource update. Management said the larger project scale, combined with consistent metallurgy and strong continuity of near-surface mineralisation, improves development flexibility and supports ongoing discussions around strategic partnerships and project funding as Orom-Cross progresses toward production planning.

    Despite the positive resource growth, the company’s outlook remains constrained by weak financial performance, including a lack of revenue, ongoing losses and increasing cash burn. Technical indicators are supportive, with the share price showing a strong upward trend and a positive MACD signal, although highly elevated RSI and stochastic readings suggest the stock may be overbought and at risk of a near-term pullback. Valuation metrics remain limited due to negative earnings and the absence of dividend support.

    More about Blencowe Resources Plc

    Blencowe Resources Plc is a London-listed exploration and development company focused on graphite projects. Its flagship asset is the 100%-owned Orom-Cross Graphite Project in Uganda, which is being developed with the aim of becoming a large-scale, long-life graphite operation. The project is positioned to supply growing global demand for graphite from both traditional industrial uses and emerging battery markets.

  • Kavango Resources Raises $8.4m to Expand Gold Operations in Zimbabwe

    Kavango Resources Raises $8.4m to Expand Gold Operations in Zimbabwe

    Kavango Resources (LSE:KAV) has secured approximately US$8.4 million through subscription agreements in both Zimbabwe and the UK, issuing around 630 million new shares at a price representing a 33% premium to the company’s recent mid-market share price. Chairman and interim CEO Peter Wynter Bee participated in the UK placing, subscribing for 20 million shares.

    The newly issued shares from the UK and VFEX tranches are expected to begin trading around 16 March 2026 following admission to the London Stock Exchange and the transfer of the Zimbabwe portion to the Victoria Falls Stock Exchange. Once combined with existing cash and previously committed funding, the company expects to have about US$13.5 million available to support its growth plans. These include expanding production at the Hillside gold project, pursuing the proposed acquisition of Nara, addressing associated litigation costs, advancing exploration programmes, and providing additional working capital for operations in Zimbabwe.

    The company’s outlook remains constrained by weak financial performance, including significant operating losses and ongoing cash outflows despite only early-stage revenue generation. However, the balance sheet shows positive equity and moderate leverage, offering some stability. Technical indicators present a mixed picture, with neutral momentum and signs of short-term stabilisation, while valuation metrics remain difficult to support given the negative price-to-earnings ratio and the absence of a dividend yield.

    More about Kavango Resources

    Kavango Resources is a metals exploration and gold production company focused on Southern Africa, with listings on both the London Stock Exchange and the Victoria Falls Stock Exchange in Zimbabwe. The group is concentrating its operations in Zimbabwe, where it aims to increase gold production while pursuing growth through acquisitions and ongoing exploration activities.

  • Altona Rare Earths Raises Capital Through Warrant Exercise to Support Monte Muambe Studies

    Altona Rare Earths Raises Capital Through Warrant Exercise to Support Monte Muambe Studies

    Altona Rare Earths (LSE:REE) has raised £74,666 after the exercise of 3,733,334 warrants priced at 2 pence each, providing additional funding for technical work at its Monte Muambe project. The proceeds will help finance a fluorspar and gallium resource estimate alongside a scoping study aimed at advancing the project’s development.

    In addition, the company has issued 625,000 new ordinary shares to a service provider in place of £15,000 in fees, reflecting its continued use of equity to cover certain project and corporate expenses. Following the issuance of a total of 4,358,334 new shares, Altona’s enlarged share capital will increase to 383,240,635 ordinary shares, all of which will be admitted to trading on the London Stock Exchange’s Main Market. While the issuance results in modest dilution for existing shareholders, it supports ongoing technical work designed to strengthen Monte Muambe’s multi-commodity potential and enhance its strategic relevance within global critical minerals supply chains.

    The company’s outlook remains constrained by weak financial fundamentals, including a lack of revenue, ongoing losses, persistent cash burn, and increasing leverage. However, technical indicators provide some positive momentum, with the share price trading well above major moving averages and supported by a positive MACD signal. Valuation metrics offer limited support given the company’s negative earnings and absence of dividend payments.

    More about Altona Energy

    Altona Rare Earths is a London Main Market-listed exploration and development company focused on critical raw materials projects in Africa. Its flagship Monte Muambe project in Mozambique contains rare earth elements alongside fluorspar and gallium, while the company also holds the Sesana copper-silver project in Botswana. Together, these assets position the group to contribute to the supply of materials essential for clean energy technologies and advanced industries.

    Monte Muambe has progressed through extensive drilling, the publication of a maiden JORC-compliant resource, the granting of a 25-year mining licence, and a scoping study focused on rare earths. Altona is also evaluating the potential for near-term fluorspar production and the recovery of gallium as a by-product, while continuing to pursue additional opportunities aligned with its strategy in critical minerals.

  • Synergia Energy Reports Higher Oil Production at Cambay Field

    Synergia Energy Reports Higher Oil Production at Cambay Field

    Synergia Energy (LSE:SYN) has reported a notable increase in oil output from two legacy wells at its onshore Cambay Production Sharing Contract (PSC) field in India. Following workover operations completed in November 2025, wells C-64 and C-74 have shown improved performance, with combined production rising from an average of 78 barrels of oil per day in February to around 195 barrels per day so far in March. The increase follows recent adjustments to pump rates aimed at enhancing recovery.

    Gas production at the field has also remained stable, with the C-77H gas well continuing to operate at a plateau level of roughly 500,000 standard cubic feet per day. The combined performance improvements across both oil and gas operations highlight stronger operational momentum at Cambay, which could support Synergia’s near-term revenue prospects and strengthen its presence in India’s onshore energy sector.

    Despite the operational progress, the company’s outlook remains constrained by weak financial performance. Revenues have declined, gross profit remains negative, and the business continues to experience operating and free cash flow outflows. Technical indicators also point to bearish momentum, with the share price trading below major moving averages and a negative MACD signal. While a very low price-to-earnings ratio offers some valuation support, it does little to offset ongoing operational and cash flow risks.

    More about Synergia Energy Ltd

    Synergia Energy Ltd is an oil and gas exploration and production company focused on onshore energy assets in India. The company holds a 50% working interest in the Cambay PSC, where it is pursuing both oil and gas development to increase hydrocarbon production and improve recovery from the field.

  • IMI Delivers Fifth Year of Organic Growth and Launches £500m Share Buyback

    IMI Delivers Fifth Year of Organic Growth and Launches £500m Share Buyback

    IMI plc (LSE:IMI) reported its fifth straight year of mid-single-digit organic revenue growth in 2025, with organic sales rising 5% and organic adjusted operating profit increasing 8%. The performance lifted the company’s adjusted operating margin to 20%. Statutory profit before tax climbed 27% during the year, while free cash flow improved to £290 million and return on invested capital rose to 14.0%, highlighting continued profitable expansion.

    Reflecting the group’s strong cash generation, the board has proposed a 10% increase in the final dividend and announced a £500 million share buyback programme. Management said the move aligns with its disciplined capital allocation approach and commitment to enhancing shareholder returns. Looking ahead to 2026, the company expects to deliver a sixth consecutive year of mid-single-digit organic revenue growth, with margins anticipated to remain stable or improve slightly. Continued momentum is forecast in the Automation and Climate Control segments, supporting management’s confidence in sustained earnings growth.

    The company’s outlook is primarily supported by strong financial results and positive corporate developments. Technical indicators suggest a bullish share price trend, although some caution is warranted due to potential overbought conditions. Valuation metrics indicate the stock may appear relatively expensive, which moderates the overall assessment. Commentary from the earnings call also reinforced confidence in the group’s strategy and growth trajectory.

    More about IMI plc

    IMI plc is a global engineering company specialising in fluid and motion control technologies. The group provides customised, high value-added solutions primarily serving Automation and Life Technology markets. Its products support key sectors linked to energy transition, industrial automation, and healthcare, while a strong aftermarket services business—accounting for roughly 45% of revenue—provides a stable and higher-margin revenue stream.

  • Hargreaves Services Sells Battery Storage Land Asset Above Valuation

    Hargreaves Services Sells Battery Storage Land Asset Above Valuation

    Hargreaves Services (LSE:HSP) has agreed to the unconditional sale of another portion of its renewable energy land portfolio, disposing of freehold land in South Lanarkshire that is leased to a battery energy storage system. The asset has been sold to Meadow Partners for £6.8 million, with completion required by 30 April 2026. The land currently generates approximately £0.5 million in annual rental income and forms part of the company’s strategy to unlock value from its renewable energy property holdings.

    The agreed price reflects a 6% premium to the £6.4 million valuation assigned to the asset in an independent assessment conducted in July 2025, when it formed part of a broader £27 million portfolio. The transaction highlights continued investor demand for infrastructure supporting grid-scale energy storage. Hargreaves expects the sale to produce a one-off benefit of around £5.3 million to profit before tax and approximately £6.0 million in cash during the financial year ending 31 May 2026, providing additional financial flexibility to support future investments or potential shareholder returns.

    The company’s outlook is supported by strong financial performance, including solid revenue growth, robust cash generation, and relatively low leverage. Technical indicators are also favourable, with the share price trading above major moving averages and supported by a positive MACD signal. Valuation metrics further strengthen the investment case, with a low price-to-earnings ratio and an attractive dividend yield. Commentary from recent earnings discussions reinforces momentum and potential capital returns, although execution risks remain around renewable land development and the group’s zinc project.

    More about Hargreaves Services

    Hargreaves Services plc is a diversified UK-based group active across the environmental, infrastructure, and property sectors, with operations spanning the UK and Southeast Asia. Its Services division delivers materials handling, mechanical and electrical contracting, logistics, and major earthworks for projects related to connectivity, clean energy, and environmental infrastructure.

    The group’s Hargreaves Land division focuses on the regeneration of brownfield sites for residential and commercial development. In addition, its German joint venture, Hargreaves Raw Materials Services, operates in specialist commodity markets and owns DK Recycling und Roheisen, a recycler of steel industry waste. Hargreaves Services is headquartered in County Durham and maintains operational centres in the UK, Hong Kong, South Africa, and Duisburg, Germany.